FDA 483 - Gland Pharma Limited - March 17, 2015
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
An FDA inspection of Gland Pharma Limited in Hyderabad, India, revealed deficiencies in their quality system. The firm's procedures for annual quality standards record evaluation were found to be inadequate, specifically regarding the tracking and trending of QC laboratory incident reports. Additionally, investigations into unexplained discrepancies lacked complete conclusions and follow-up, including insufficient preventive actions for out-of-specification observations.
ID · e76b5f6e-2c1e-45b0-9c0e-e037a8f686a1